Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

Fast and fierce versus slow and smooth: Heterogeneity in immune responses to Plasmodium in the controlled human malaria infection model.

Yap XZ, McCall MBB, Sauerwein RW.

Immunol Rev. 2019 Oct 12. doi: 10.1111/imr.12811. [Epub ahead of print] Review.

PMID:
31605396
2.

Antimalarial pantothenamide metabolites target acetyl-coenzyme A biosynthesis in Plasmodium falciparum.

Schalkwijk J, Allman EL, Jansen PAM, de Vries LE, Verhoef JMJ, Jackowski S, Botman PNM, Beuckens-Schortinghuis CA, Koolen KMJ, Bolscher JM, Vos MW, Miller K, Reeves SA, Pett H, Trevitt G, Wittlin S, Scheurer C, Sax S, Fischli C, Angulo-Barturen I, Jiménez-Diaz MB, Josling G, Kooij TWA, Bonnert R, Campo B, Blaauw RH, Rutjes FPJT, Sauerwein RW, Llinás M, Hermkens PHH, Dechering KJ.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaas9917. doi: 10.1126/scitranslmed.aas9917.

PMID:
31534021
3.

A Novel Tool for the Generation of Conditional Knockouts To Study Gene Function across the Plasmodium falciparum Life Cycle.

Tibúrcio M, Yang ASP, Yahata K, Suárez-Cortés P, Belda H, Baumgarten S, van de Vegte-Bolmer M, van Gemert GJ, van Waardenburg Y, Levashina EA, Sauerwein RW, Treeck M.

MBio. 2019 Sep 17;10(5). pii: e01170-19. doi: 10.1128/mBio.01170-19.

4.

Transforming growth factor-beta profiles correlate with clinical symptoms and parameters of haemostasis and inflammation in a controlled human malaria infection.

de Jong GM, McCall MBB, Dik WA, Urbanus RT, Wammes LJ, Koelewijn R, Sauerwein RW, Verbon A, van Hellemond JJ, van Genderen PJJ.

Cytokine. 2019 Sep 13;125:154838. doi: 10.1016/j.cyto.2019.154838. [Epub ahead of print]

PMID:
31525609
5.

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum.

Singh SK, Thrane S, Chourasia BK, Teelen K, Graumans W, Stoter R, van Gemert GJ, van de Vegte-Bolmer MG, Nielsen MA, Salanti A, Sander AF, Sauerwein RW, Jore MM, Theisen M.

Front Immunol. 2019 Jun 5;10:1256. doi: 10.3389/fimmu.2019.01256. eCollection 2019.

6.

Whole-blood transcriptomic signatures induced during immunization by chloroquine prophylaxis and Plasmodium falciparum sporozoites.

Tran TM, Bijker EM, Haks MC, Ottenhoff THM, Visser L, Schats R, Venepally P, Lorenzi H, Crompton PD, Sauerwein RW.

Sci Rep. 2019 Jun 10;9(1):8386. doi: 10.1038/s41598-019-44924-7.

7.

TH1-Polarized TFH Cells Delay Naturally-Acquired Immunity to Malaria.

Yap XZ, Hustin LSP, Sauerwein RW.

Front Immunol. 2019 May 17;10:1096. doi: 10.3389/fimmu.2019.01096. eCollection 2019. Review.

8.

The XN-30 hematology analyzer for rapid sensitive detection of malaria: a diagnostic accuracy study.

Post A, Kaboré B, Reuling IJ, Bognini J, van der Heijden W, Diallo S, Lompo P, Kam B, Herssens N, Lanke K, Bousema T, Sauerwein RW, Tinto H, Jacobs J, de Mast Q, van der Ven AJ.

BMC Med. 2019 May 31;17(1):103. doi: 10.1186/s12916-019-1334-5.

9.

A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages.

Marin-Mogollon C, Salman AM, Koolen KMJ, Bolscher JM, van Pul FJA, Miyazaki S, Imai T, Othman AS, Ramesar J, van Gemert GJ, Kroeze H, Chevalley-Maurel S, Franke-Fayard B, Sauerwein RW, Hill AVS, Dechering KJ, Janse CJ, Khan SM.

Front Cell Infect Microbiol. 2019 Apr 16;9:96. doi: 10.3389/fcimb.2019.00096. eCollection 2019.

10.

Author Correction: The Plasmodium falciparum male gametocyte protein P230p, a paralog of P230, is vital for ookinete formation and mosquito transmission.

Marin-Mogollon C, van de Vegte-Bolmer M, van Gemert GJ, van Pul FJA, Ramesar J, Othman AS, Kroeze H, Miao J, Cui L, Williamson KC, Sauerwein RW, Janse CJ, Khan SM.

Sci Rep. 2019 May 3;9(1):7061. doi: 10.1038/s41598-019-43505-y.

11.

Outcomes of controlled human malaria infection after BCG vaccination.

Walk J, de Bree LCJ, Graumans W, Stoter R, van Gemert GJ, van de Vegte-Bolmer M, Teelen K, Hermsen CC, Arts RJW, Behet MC, Keramati F, Moorlag SJCFM, Yang ASP, van Crevel R, Aaby P, de Mast Q, van der Ven AJAM, Stabell Benn C, Netea MG, Sauerwein RW.

Nat Commun. 2019 Feb 20;10(1):874. doi: 10.1038/s41467-019-08659-3.

12.

Antibody Biomarkers Associated with Sterile Protection Induced by Controlled Human Malaria Infection under Chloroquine Prophylaxis.

Obiero JM, Campo JJ, Scholzen A, Randall A, Bijker EM, Roestenberg M, Hermsen CC, Teng A, Jain A, Davies DH, Sauerwein RW, Felgner PL.

mSphere. 2019 Feb 20;4(1). pii: e00027-19. doi: 10.1128/mSphereDirect.00027-19.

13.

Can Patrolling Liver-Resident T Cells Control Human Malaria Parasite Development?

Walk J, Stok JE, Sauerwein RW.

Trends Immunol. 2019 Mar;40(3):186-196. doi: 10.1016/j.it.2019.01.002. Epub 2019 Jan 31. Review.

PMID:
30713008
14.

Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate.

Mendes AM, Reuling IJ, Andrade CM, Otto TD, Machado M, Teixeira F, Pissarra J, Gonçalves-Rosa N, Bonaparte D, Sinfrónio J, Sanders M, Janse CJ, Khan SM, Newbold CI, Berriman M, Lee CK, Wu Y, Ockenhouse CF, Sauerwein RW, Prudêncio M.

NPJ Vaccines. 2018 Nov 27;3:54. doi: 10.1038/s41541-018-0091-3. eCollection 2018.

15.

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.

Kundu P, Semesi A, Jore MM, Morin MJ, Price VL, Liang A, Li J, Miura K, Sauerwein RW, King CR, Julien JP.

Nat Commun. 2018 Oct 26;9(1):4458. doi: 10.1038/s41467-018-06742-9.

16.

The Plasmodium falciparum male gametocyte protein P230p, a paralog of P230, is vital for ookinete formation and mosquito transmission.

Marin-Mogollon C, van de Vegte-Bolmer M, van Gemert GJ, van Pul FJA, Ramesar J, Othman AS, Kroeze H, Miao J, Cui L, Williamson KC, Sauerwein RW, Janse CJ, Khan SM.

Sci Rep. 2018 Oct 8;8(1):14902. doi: 10.1038/s41598-018-33236-x. Erratum in: Sci Rep. 2019 May 3;9(1):7061.

17.

Liver Injury in Uncomplicated Malaria is an Overlooked Phenomenon: An Observational Study.

Reuling IJ, de Jong GM, Yap XZ, Asghar M, Walk J, van de Schans LA, Koelewijn R, Färnert A, de Mast Q, van der Ven AJ, Bousema T, van Hellemond JJ, van Genderen PJJ, Sauerwein RW.

EBioMedicine. 2018 Oct;36:131-139. doi: 10.1016/j.ebiom.2018.09.018. Epub 2018 Sep 19. No abstract available.

18.

Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody.

Lennartz F, Brod F, Dabbs R, Miura K, Mekhaiel D, Marini A, Jore MM, Søgaard MM, Jørgensen T, de Jongh WA, Sauerwein RW, Long CA, Biswas S, Higgins MK.

Nat Commun. 2018 Sep 20;9(1):3822. doi: 10.1038/s41467-018-06340-9.

19.

A Plasmodium berghei sporozoite-based vaccination platform against human malaria.

Mendes AM, Machado M, Gonçalves-Rosa N, Reuling IJ, Foquet L, Marques C, Salman AM, Yang ASP, Moser KA, Dwivedi A, Hermsen CC, Jiménez-Díaz B, Viera S, Santos JM, Albuquerque I, Bhatia SN, Bial J, Angulo-Barturen I, Silva JC, Leroux-Roels G, Janse CJ, Khan SM, Mota MM, Sauerwein RW, Prudêncio M.

NPJ Vaccines. 2018 Aug 24;3:33. doi: 10.1038/s41541-018-0068-2. eCollection 2018.

20.

Controlled Human Malaria Infection with Graded Numbers of Plasmodium falciparum NF135.C10- or NF166.C8-Infected Mosquitoes.

Langenberg MCC, Wammes LJ, McCall MBB, Bijker EM, van Gemert GJ, Graumans W, van de Vegte-Bolmer MG, Teelen K, Hermsen CC, Koelewijn R, van Hellemond JJ, van Genderen PJJ, Sauerwein RW.

Am J Trop Med Hyg. 2018 Sep;99(3):709-712. doi: 10.4269/ajtmh.18-0194. Epub 2018 Jul 12.

21.

Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases.

Miglianico M, Eldering M, Slater H, Ferguson N, Ambrose P, Lees RS, Koolen KMJ, Pruzinova K, Jancarova M, Volf P, Koenraadt CJM, Duerr HP, Trevitt G, Yang B, Chatterjee AK, Wisler J, Sturm A, Bousema T, Sauerwein RW, Schultz PG, Tremblay MS, Dechering KJ.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):E6920-E6926. doi: 10.1073/pnas.1801338115. Epub 2018 Jul 2.

22.

Predicting the likelihood and intensity of mosquito infection from sex specific Plasmodium falciparum gametocyte density.

Bradley J, Stone W, Da DF, Morlais I, Dicko A, Cohuet A, Guelbeogo WM, Mahamar A, Nsango S, Soumaré HM, Diawara H, Lanke K, Graumans W, Siebelink-Stoter R, van de Vegte-Bolmer M, Chen I, Tiono A, Gonçalves BP, Gosling R, Sauerwein RW, Drakeley C, Churcher TS, Bousema T.

Elife. 2018 May 31;7. pii: e34463. doi: 10.7554/eLife.34463.

23.

Modeling the impact of Plasmodium falciparum sexual stage immunity on the composition and dynamics of the human infectious reservoir for malaria in natural settings.

Ouédraogo AL, Eckhoff PA, Luty AJF, Roeffen W, Sauerwein RW, Bousema T, Wenger EA.

PLoS Pathog. 2018 May 9;14(5):e1007034. doi: 10.1371/journal.ppat.1007034. eCollection 2018 May.

24.

The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization with Plasmodium falciparum Malaria Sporozoites.

Behet MC, Kurtovic L, van Gemert GJ, Haukes CM, Siebelink-Stoter R, Graumans W, van de Vegte-Bolmer MG, Scholzen A, Langereis JD, Diavatopoulos DA, Beeson JG, Sauerwein RW.

Infect Immun. 2018 Jun 21;86(7). pii: e00920-17. doi: 10.1128/IAI.00920-17. Print 2018 Jul.

25.

Mosquito Infectivity and Parasitemia after Controlled Human Malaria Infection.

Walk J, van Gemert GJ, Graumans W, Sauerwein RW, Bijker EM.

Am J Trop Med Hyg. 2018 Jun;98(6):1705-1708. doi: 10.4269/ajtmh.17-0952. Epub 2018 Apr 26.

26.

Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children.

Kurtovic L, Behet MC, Feng G, Reiling L, Chelimo K, Dent AE, Mueller I, Kazura JW, Sauerwein RW, Fowkes FJI, Beeson JG.

BMC Med. 2018 Apr 30;16(1):61. doi: 10.1186/s12916-018-1054-2.

27.

Plasmodium-associated changes in human odor attract mosquitoes.

Robinson A, Busula AO, Voets MA, Beshir KB, Caulfield JC, Powers SJ, Verhulst NO, Winskill P, Muwanguzi J, Birkett MA, Smallegange RC, Masiga DK, Mukabana WR, Sauerwein RW, Sutherland CJ, Bousema T, Pickett JA, Takken W, Logan JG, de Boer JG.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4209-E4218. doi: 10.1073/pnas.1721610115. Epub 2018 Apr 16.

28.

A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model.

Reuling IJ, van de Schans LA, Coffeng LE, Lanke K, Meerstein-Kessel L, Graumans W, van Gemert GJ, Teelen K, Siebelink-Stoter R, van de Vegte-Bolmer M, de Mast Q, van der Ven AJ, Ivinson K, Hermsen CC, de Vlas S, Bradley J, Collins KA, Ockenhouse CF, McCarthy J, Sauerwein RW, Bousema T.

Elife. 2018 Feb 27;7. pii: e31549. doi: 10.7554/eLife.31549.

29.

A Macrophage Colony-Stimulating-Factor-Producing γδ T Cell Subset Prevents Malarial Parasitemic Recurrence.

Mamedov MR, Scholzen A, Nair RV, Cumnock K, Kenkel JA, Oliveira JHM, Trujillo DL, Saligrama N, Zhang Y, Rubelt F, Schneider DS, Chien YH, Sauerwein RW, Davis MM.

Immunity. 2018 Feb 20;48(2):350-363.e7. doi: 10.1016/j.immuni.2018.01.009. Epub 2018 Feb 6.

30.

Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice.

Sack BK, Mikolajczak SA, Fishbaugher M, Vaughan AM, Flannery EL, Nguyen T, Betz W, Jane Navarro M, Foquet L, Steel RWJ, Billman ZP, Murphy SC, Hoffman SL, Chakravarty S, Sim BKL, Behet M, Reuling IJ, Walk J, Scholzen A, Sauerwein RW, Ishizuka AS, Flynn B, Seder RA, Kappe SHI.

NPJ Vaccines. 2017 Oct 9;2:27. doi: 10.1038/s41541-017-0028-2. eCollection 2017.

31.

Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission.

Dechering KJ, Duerr HP, Koolen KMJ, Gemert GV, Bousema T, Burrows J, Leroy D, Sauerwein RW.

Sci Rep. 2017 Dec 15;7(1):17680. doi: 10.1038/s41598-017-16671-0.

32.

Changes in total and differential leukocyte counts during the clinically silent liver phase in a controlled human malaria infection in malaria-naïve Dutch volunteers.

van Wolfswinkel ME, Langenberg MCC, Wammes LJ, Sauerwein RW, Koelewijn R, Hermsen CC, van Hellemond JJ, van Genderen PJ.

Malar J. 2017 Nov 10;16(1):457. doi: 10.1186/s12936-017-2108-1.

33.

Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates.

van der Velden M, Bilos A, van den Heuvel JJMW, Rijpma SR, Hurkmans EGE, Sauerwein RW, Russel FGM, Koenderink JB.

Malar J. 2017 Oct 23;16(1):422. doi: 10.1186/s12936-017-2062-y.

34.

Comparative assessment of An. gambiae and An. stephensi mosquitoes to determine transmission-reducing activity of antibodies against P. falciparum sexual stage antigens.

Eldering M, Bompard A, Miura K, Stone W, Morlais I, Cohuet A, van Gemert GJ, Brock PM, Rijpma SR, van de Vegte-Bolmer M, Graumans W, Siebelink-Stoter R, Da DF, Long CA, Morin MJ, Sauerwein RW, Churcher TS, Bousema T.

Parasit Vectors. 2017 Oct 17;10(1):489. doi: 10.1186/s13071-017-2414-z.

35.

Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial.

Walk J, Reuling IJ, Behet MC, Meerstein-Kessel L, Graumans W, van Gemert GJ, Siebelink-Stoter R, van de Vegte-Bolmer M, Janssen T, Teelen K, de Wilt JHW, de Mast Q, van der Ven AJ, Diez Benavente E, Campino S, Clark TG, Huynen MA, Hermsen CC, Bijker EM, Scholzen A, Sauerwein RW.

BMC Med. 2017 Sep 13;15(1):168. doi: 10.1186/s12916-017-0923-4.

36.

Protective immunity differs between routes of administration of attenuated malaria parasites independent of parasite liver load.

Haeberlein S, Chevalley-Maurel S, Ozir-Fazalalikhan A, Koppejan H, Winkel BMF, Ramesar J, Khan SM, Sauerwein RW, Roestenberg M, Janse CJ, Smits HH, Franke-Fayard B.

Sci Rep. 2017 Sep 4;7(1):10372. doi: 10.1038/s41598-017-10480-1.

37.

Gametocytemia and Attractiveness of Plasmodium falciparum-Infected Kenyan Children to Anopheles gambiae Mosquitoes.

Busula AO, Bousema T, Mweresa CK, Masiga D, Logan JG, Sauerwein RW, Verhulst NO, Takken W, de Boer JG.

J Infect Dis. 2017 Aug 1;216(3):291-295. doi: 10.1093/infdis/jix214.

PMID:
28859429
38.

Odours of Plasmodium falciparum-infected participants influence mosquito-host interactions.

de Boer JG, Robinson A, Powers SJ, Burgers SLGE, Caulfield JC, Birkett MA, Smallegange RC, van Genderen PJJ, Bousema T, Sauerwein RW, Pickett JA, Takken W, Logan JG.

Sci Rep. 2017 Aug 24;7(1):9283. doi: 10.1038/s41598-017-08978-9.

39.

Concentration of Plasmodium falciparum gametocytes in whole blood samples by magnetic cell sorting enhances parasite infection rates in mosquito feeding assays.

Reuling IJ, Stone WJR, van de Vegte-Bolmer M, van Gemert GJ, Siebelink-Stoter R, Graumans W, Lanke K, Bousema T, Sauerwein RW.

Malar J. 2017 Aug 5;16(1):315. doi: 10.1186/s12936-017-1959-9.

40.

Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.

Mistarz UH, Singh SK, Nguyen TTTN, Roeffen W, Yang F, Lissau C, Madsen SM, Vrang A, Tiendrebeogo RW, Kana IH, Sauerwein RW, Theisen M, Rand KD.

Pharm Res. 2017 Sep;34(9):1970-1983. doi: 10.1007/s11095-017-2208-1. Epub 2017 Jun 23.

PMID:
28646324
41.

Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers.

McCall MBB, Wammes LJ, Langenberg MCC, van Gemert GJ, Walk J, Hermsen CC, Graumans W, Koelewijn R, Franetich JF, Chishimba S, Gerdsen M, Lorthiois A, van de Vegte M, Mazier D, Bijker EM, van Hellemond JJ, van Genderen PJJ, Sauerwein RW.

Sci Transl Med. 2017 Jun 21;9(395). pii: eaag2490. doi: 10.1126/scitranslmed.aag2490.

PMID:
28637923
42.

Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine.

Singh SK, Roeffen W, Mistarz UH, Chourasia BK, Yang F, Rand KD, Sauerwein RW, Theisen M.

Microb Cell Fact. 2017 May 31;16(1):97. doi: 10.1186/s12934-017-0710-0.

43.

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.

Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ, Bantscheff M, Ruecker A, Blagborough AM, Zakutansky SE, Zeeman AM, White KL, Shackleford DM, Mannila J, Morizzi J, Scheurer C, Angulo-Barturen I, Martínez MS, Ferrer S, Sanz LM, Gamo FJ, Reader J, Botha M, Dechering KJ, Sauerwein RW, Tungtaeng A, Vanachayangkul P, Lim CS, Burrows J, Witty MJ, Marsh KC, Bodenreider C, Rochford R, Solapure SM, Jiménez-Díaz MB, Wittlin S, Charman SA, Donini C, Campo B, Birkholtz LM, Hanson KK, Drewes G, Kocken CHM, Delves MJ, Leroy D, Fidock DA, Waterson D, Street LJ, Chibale K.

Sci Transl Med. 2017 Apr 26;9(387). pii: eaad9735. doi: 10.1126/scitranslmed.aad9735.

44.

The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection.

Coffeng LE, Hermsen CC, Sauerwein RW, de Vlas SJ.

PLoS Comput Biol. 2017 Jan 12;13(1):e1005255. doi: 10.1371/journal.pcbi.1005255. eCollection 2017 Jan.

45.

[Splenomegaly in an Eritrean refugee: the hyper-reactive malaria splenomegaly syndrome.]

Cruijsen MM, Reuling IJ, Keuter M, Sauerwein RW, van der Ven AJ, de Mast Q.

Ned Tijdschr Geneeskd. 2016;160:D444. Dutch.

PMID:
27848905
46.

Erratum to: Diagnosis and treatment based on quantitative PCR after controlled human malaria infection.

Walk J, Schats R, Langenberg MCC, Reuling IJ, Teelen K, Roestenberg M, Hermsen CC, Visser LG, Sauerwein RW.

Malar J. 2016 Oct 28;15:522. doi: 10.1186/s12936-016-1571-4. eCollection 2016.

47.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.

Le Bihan A, de Kanter R, Angulo-Barturen I, Binkert C, Boss C, Brun R, Brunner R, Buchmann S, Burrows J, Dechering KJ, Delves M, Ewerling S, Ferrer S, Fischli C, Gamo-Benito FJ, Gnädig NF, Heidmann B, Jiménez-Díaz MB, Leroy D, Martínez MS, Meyer S, Moehrle JJ, Ng CL, Noviyanti R, Ruecker A, Sanz LM, Sauerwein RW, Scheurer C, Schleiferboeck S, Sinden R, Snyder C, Straimer J, Wirjanata G, Marfurt J, Price RN, Weller T, Fischli W, Fidock DA, Clozel M, Wittlin S.

PLoS Med. 2016 Oct 4;13(10):e1002138. doi: 10.1371/journal.pmed.1002138. eCollection 2016 Oct.

48.

An inter-laboratory comparison of standard membrane-feeding assays for evaluation of malaria transmission-blocking vaccines.

Miura K, Stone WJ, Koolen KM, Deng B, Zhou L, van Gemert GJ, Locke E, Morin M, Bousema T, Sauerwein RW, Long CA, Dechering KJ.

Malar J. 2016 Sep 9;15:463. doi: 10.1186/s12936-016-1515-z.

49.

Transcriptomic evidence for modulation of host inflammatory responses during febrile Plasmodium falciparum malaria.

Tran TM, Jones MB, Ongoiba A, Bijker EM, Schats R, Venepally P, Skinner J, Doumbo S, Quinten E, Visser LG, Whalen E, Presnell S, O'Connell EM, Kayentao K, Doumbo OK, Chaussabel D, Lorenzi H, Nutman TB, Ottenhoff TH, Haks MC, Traore B, Kirkness EF, Sauerwein RW, Crompton PD.

Sci Rep. 2016 Aug 10;6:31291. doi: 10.1038/srep31291.

50.

Diagnosis and treatment based on quantitative PCR after controlled human malaria infection.

Walk J, Schats R, Langenberg MC, Reuling IJ, Teelen K, Roestenberg M, Hermsen CC, Visser LG, Sauerwein RW.

Malar J. 2016 Aug 5;15(1):398. doi: 10.1186/s12936-016-1434-z. Erratum in: Malar J. 2016 Oct 28;15(1):522. Malar J. 2016 Oct 28;15:522.

Supplemental Content

Loading ...
Support Center